Rebinyn HCP Email: “3 important considerations regarding rFIX treatments”




Brand: Rebinyn (coagulation factor IX (recombinant), GlycoPEGylated), Intravenous Infusion
Parent Company: Novo Nordisk
Drug Type: Prescription
Drug Category: Hematology
Campaign: Post-Launch
Targeting: HCPs
Patient Website: https://www.rebinyn.com/
HCP Website: https://www.rebinynpro.com

Subject line: 3 important considerations regarding rFIX treatments

Sent on: Aug 16, 2018 at 7AM

From: Novo Nordisk

Pre-header: Providing more for your patients with hemophilia B.